Actinogen is advancing a revolutionary oral therapeutic, Xanamem^®, through pivotal trials to transform treatment for Alzheimer’s disease and major depressive disorder. Our vision is to improve lives by targeting brain cortisol with precision and innovation.

ACW receives further $1.9m FY2025 R&D rebate from the ATO

Actinogen has received a further research and development tax incentive (RDTI) rebate of almost $1.9m from the ATO. This further rebate relates to overseas R&D expenditure incurred in FY2025 that remained subject to receipt of an Advanced Overseas Finding approval at the time of lodging the Company’s tax return.
When combined with the initial RDTI rebate of ~$5.5m received in October 2025, the total RDTI rebate received by ACW for the FY2025 year is $7.4m.

Share Purchase Plan booklet & letter to eligible shareholders

ACW announced a Share Purchase Plan (SPP) for eligible shareholders in Australia and New Zealand on 2  February 2026.  The SPP has now opened and an SPP booklet and letter to eligible shareholders have been released (10 February). The SPP closes at 5pm (AEDT) on 24 February 2026.

Read the sample letter to eligible shareholders here.

ACW secures funding beyond XanaMIA AD trial final results

Actinogen secures funding beyond the XanaMIA Alzheimer’s disease trial topline final results in November following the recent positive interim analysis outcome. A share placement and share purchase plan have been announced to raise up to approximately $17.0 million.

ACW December 2025 quarterly activity report & Appendix 4C

Actinogen has released its quarterly activity report and Appendix 4C f or the three-month period ended 31 December 2025.

ACW positive XanaMIA AD trial Interim Analysis outcome

The XanaMIA pivotal Alzheimer’s disease (AD) trial’s independent Data Monitoring Committee (DMC) has recommended that the trial continue without amendment after its interim analysis. In doing so, the DMC determined that the unblinded safety and efficacy data it reviewed support continuing the trial to its completion later in the year

ACW secures $4.3m of non-dilutive R&D tax funding

Actinogen has secured a second tranche of non-dilutive funding from Endpoints Capital worth $4.3m under a funding facility secured against the company’s forecast FY26 Research and Development Tax Incentive rebate.

The funding is provided by Endpoints as part of the overall funding package of up to $13.8m as announced on 30 June 2025.